BMP4-GPX4 Axis Improves Retinal Ganglion Cell Fate in NMDA-Induced Glaucoma: Evidence and Implications

Study Background and Research Question

Glaucoma remains a leading cause of irreversible blindness, with elevated intraocular pressure (IOP) inducing progressive retinal ganglion cell (RGC) death. Mechanistic studies have increasingly implicated ferroptosis—an iron-dependent form of cell death characterized by excessive reactive oxygen species (ROS) and lipid peroxidation—in the pathophysiology of high IOP glaucoma. While retinal stem cell (RSC) transplantation offers the potential to replenish lost RGCs, the differentiation and survival of grafted cells are often limited by the hostile, oxidative retinal environment. The reference study by Fang et al. (2025) addresses whether modulating the bone morphogenetic protein 4 (BMP4)–glutathione peroxidase 4 (GPX4) axis can mitigate ferroptosis and promote RSC differentiation in a mouse glaucoma model.

Key Innovation from the Reference Study

The central advance of this work is the mechanistic demonstration that BMP4 upregulation, via its downstream effector GPX4, significantly reduces ferroptosis and enhances the integration and differentiation potential of transplanted RSCs in the glaucomatous retina. This dual action—both cytoprotection and facilitation of stem cell fate—marks a novel therapeutic approach for neurodegenerative eye disease. The study also provides a direct link between BMP4-GPX4 signaling and the inhibition of oxidative stress and iron accumulation in the context of RGC injury.

Methods and Experimental Design Insights

To recapitulate the excitotoxic and ferroptotic environment of high IOP glaucoma, the authors employed N-Methyl-D-aspartic acid (NMDA) as an experimental tool to induce acute RGC damage in mice. NMDA, a selective NMDA receptor agonist, models excitotoxicity by promoting robust calcium influx and oxidative stress, thereby triggering RGC loss and visual impairment. Immunofluorescence detection of Brn3a—a marker for RGCs—confirmed the successful establishment of the glaucoma phenotype post-NMDA administration. The study further combined transcriptomic analysis (KEGG enrichment of GEO dataset GSE236302), quantitative PCR, and western blotting to assess the expression of BMP4 and its downstream SMAD signaling components in damaged retinas. Markers of ferroptosis, including ROS, glutathione (GSH), malondialdehyde (MDA), and ferrous iron (Fe2+), were quantified to evaluate the oxidative status. Transplantation of RSCs, with or without BMP4-GPX4 modulation, allowed the authors to assess the functional impact of the pathway on cell fate and neuroprotection.

Protocol Parameters

• NMDA-induced injury: Intraocular injection of NMDA to establish an acute glaucoma model and induce RGC loss, as detailed in the reference study.
• Immunofluorescence analysis: Brn3a staining for RGC quantification; 50 μm scale bar for microscopy.
• Gene and protein assays: Quantitative PCR and western blotting to measure BMP4, SMAD1/3/5, GPX4, ACSL4, and SLC7A11 expression.
• Oxidative stress assays: ROS, GSH, MDA, and Fe2+ detection to assess ferroptosis phenotype.
• Retinal stem cell transplantation: Administration of RSCs into the glaucomatous retina, with monitoring of differentiation and survival in the presence or absence of BMP4-GPX4 modulation.

Core Findings and Why They Matter

Fang et al. (2025) first established that NMDA-induced injury led to a marked decrease in Brn3a-positive RGCs, recapitulating the RGC loss seen in human glaucoma. Transcriptomic and western analyses revealed significant upregulation of BMP4 and its downstream SMAD1/3/5 signaling axis in the damaged retina. Crucially, ferroptosis markers—including increased ROS, elevated MDA, and iron accumulation—were all upregulated in the NMDA model, while GSH levels declined, confirming an oxidative stress-dominated cell death pathway.

Intervention at the BMP4-GPX4 axis produced two notable effects: (1) decreased ROS and iron accumulation, signifying efficient suppression of ferroptosis, and (2) improved survival and differentiation of transplanted RSCs into mature RGCs. Western blot data confirmed higher GPX4 expression—a key enzyme for detoxifying lipid peroxides—following BMP4 pathway activation. This dovetails with the known role of GPX4 in maintaining redox homeostasis and preventing ferroptotic cell death. The net result was not only enhanced neuroprotection for endogenous RGCs but also greater functional recovery following stem cell therapy.

Comparison with Existing Internal Articles

The mechanistic use of NMDA to induce excitotoxic injury aligns closely with prior thought-leadership perspectives, such as "Mechanistic Insights and Translational Strategy" and "Precision Excitotoxicity Models Refined by BMP4-GPX4 Insights", both of which highlight NMDA’s utility in modeling oxidative damage and neurodegeneration. However, the current reference study advances the field by directly integrating BMP4-GPX4 modulation into the NMDA-induced excitotoxicity workflow. This represents a step beyond conventional oxidative stress assay endpoints, suggesting that researchers can now leverage specific pathway modulation—not just injury induction—for both mechanistic dissection and therapeutic evaluation. Additionally, the internal article on "Modeling of Excitotoxicity and Ferroptosis" underlines the importance of robust, reproducible NMDA-induced models in the context of neurodegenerative disease, which is exemplified by the reference study’s protocol.

Limitations and Transferability

While the study provides compelling evidence that BMP4-GPX4 modulation can rescue RGCs from ferroptosis and promote stem cell integration, several caveats merit discussion. The acute NMDA-injection model, while widely accepted for excitotoxicity research, may not fully recapitulate the chronic, multifactorial nature of human glaucoma. The focus on the BMP4-GPX4 axis, although mechanistically justified, does not address other parallel cell death pathways (such as apoptosis or necroptosis) that may also affect RGC fate. Moreover, the transferability of findings from murine models to human clinical contexts remains to be validated. Additional studies will be required to determine the optimal timing, dosing, and delivery methods for BMP4 or GPX4 modulators in the context of stem cell transplantation.

Research Support Resources

For laboratories seeking to replicate or extend this workflow, NMDA (N-Methyl-D-aspartic acid) (SKU B1624, APExBIO) is a high-purity, research-grade NMDA receptor agonist suitable for experimental induction of excitotoxicity and calcium influx measurement in neurodegenerative disease models. The product’s solubility and receptor specificity facilitate reproducible modeling of oxidative stress and ferroptosis, as described in Fang et al. (2025). Researchers may consult related internal articles for additional guidance on experimental design and pathway analysis.